Man Group plc Acquires Shares of 170,907 Alnylam Pharmaceuticals, Inc. $ALNY

Man Group plc bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm bought 170,907 shares of the biopharmaceutical company’s stock, valued at approximately $51,448,000.

Several other hedge funds and other institutional investors also recently modified their holdings of ALNY. Daiwa Securities Group Inc. lifted its position in shares of Alnylam Pharmaceuticals by 0.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock worth $4,220,000 after buying an additional 35 shares during the last quarter. Golden State Wealth Management LLC grew its position in Alnylam Pharmaceuticals by 100.0% in the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 36 shares during the last quarter. Coldstream Capital Management Inc. raised its stake in Alnylam Pharmaceuticals by 2.4% during the third quarter. Coldstream Capital Management Inc. now owns 1,640 shares of the biopharmaceutical company’s stock worth $748,000 after acquiring an additional 38 shares in the last quarter. Atlantic Union Bankshares Corp raised its stake in Alnylam Pharmaceuticals by 20.9% during the fourth quarter. Atlantic Union Bankshares Corp now owns 231 shares of the biopharmaceutical company’s stock worth $92,000 after acquiring an additional 40 shares in the last quarter. Finally, Laird Norton Wetherby Wealth Management LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 3.3% in the third quarter. Laird Norton Wetherby Wealth Management LLC now owns 1,266 shares of the biopharmaceutical company’s stock worth $577,000 after acquiring an additional 40 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the transaction, the director owned 1,582 shares in the company, valued at approximately $473,302.76. This trade represents a 70.77% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.86% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ALNY. Citigroup decreased their price target on shares of Alnylam Pharmaceuticals from $380.00 to $340.00 and set a “buy” rating on the stock in a report on Monday, August 3rd. Raymond James Financial raised shares of Alnylam Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $420.00 target price on the stock in a research note on Monday, August 3rd. Truist Financial dropped their price target on Alnylam Pharmaceuticals from $410.00 to $315.00 and set a “buy” rating for the company in a research note on Tuesday, August 4th. Chardan Capital reissued a “buy” rating and set a $425.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, July 31st. Finally, Sanford C. Bernstein reaffirmed an “outperform” rating and issued a $376.00 target price on shares of Alnylam Pharmaceuticals in a report on Tuesday. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $386.14.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $239.00 on Thursday. The company has a market capitalization of $31.98 billion, a price-to-earnings ratio of 44.42 and a beta of 0.30. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75. Alnylam Pharmaceuticals, Inc. has a twelve month low of $197.81 and a twelve month high of $495.55. The stock has a fifty day simple moving average of $264.27 and a 200 day simple moving average of $294.77.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 EPS for the quarter, beating analysts’ consensus estimates of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The firm had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.32 billion. During the same quarter in the previous year, the company posted ($0.51) EPS. The business’s revenue was up 66.9% on a year-over-year basis. Sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post 6.59 EPS for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.